307 related articles for article (PubMed ID: 17298959)
21. Malignant ascites: systematic review and guideline for treatment.
Becker G; Galandi D; Blum HE
Eur J Cancer; 2006 Mar; 42(5):589-97. PubMed ID: 16434188
[TBL] [Abstract][Full Text] [Related]
22. Malignant Ascites: Validation of a Novel Ascites Symptom Mini-Scale for Use in Patients With Ovarian Cancer.
Eitan R; Raban O; Tsoref D; Jakobson-Setton A; Sabah G; Salman L; Yeoshua E; Ben-Haroush A
Int J Gynecol Cancer; 2018 Jul; 28(6):1162-1166. PubMed ID: 29664840
[TBL] [Abstract][Full Text] [Related]
23. A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites.
Barni S; Cabiddu M; Ghilardi M; Petrelli F
Crit Rev Oncol Hematol; 2011 Aug; 79(2):144-53. PubMed ID: 20708947
[TBL] [Abstract][Full Text] [Related]
24. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study.
Ginés P; Arroyo V; Quintero E; Planas R; Bory F; Cabrera J; Rimola A; Viver J; Camps J; Jiménez W
Gastroenterology; 1987 Aug; 93(2):234-41. PubMed ID: 3297907
[TBL] [Abstract][Full Text] [Related]
25. Liver metastases from adenocarcinomas of unknown primary site: management and prognosis in 68 consecutive patients.
Algin E; Ozet A; Gumusay O; Yilmaz G; Buyukberber S; Coskun U; Baykara M; Cetin B; Yıldız R; Benekli M
Wien Klin Wochenschr; 2016 Jan; 128(1-2):42-7. PubMed ID: 26373751
[TBL] [Abstract][Full Text] [Related]
26. Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications.
Hicks AM; Chou J; Capanu M; Lowery MA; Yu KH; O'Reilly EM
Clin Colorectal Cancer; 2016 Dec; 15(4):360-368. PubMed ID: 27262896
[TBL] [Abstract][Full Text] [Related]
27. Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients: a retrospective controlled cohort study.
Yamada Y; Inui K; Hara Y; Fuji K; Sonoda K; Hashimoto K; Kamijo Y
Sci Rep; 2019 Jul; 9(1):10195. PubMed ID: 31308465
[TBL] [Abstract][Full Text] [Related]
28. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Gotlieb WH; Amant F; Advani S; Goswami C; Hirte H; Provencher D; Somani N; Yamada SD; Tamby JF; Vergote I
Lancet Oncol; 2012 Feb; 13(2):154-62. PubMed ID: 22192729
[TBL] [Abstract][Full Text] [Related]
29. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study.
Planas R; Ginès P; Arroyo V; Llach J; Panés J; Vargas V; Salmerón JM; Ginès A; Toledo C; Rimola A
Gastroenterology; 1990 Dec; 99(6):1736-44. PubMed ID: 1699835
[TBL] [Abstract][Full Text] [Related]
30. [Paracentesis in the treatment of ascites in cirrhotic patients].
Uriz Otano J; Sort P; Arroyo V
Gastroenterol Hepatol; 1999; 22(7):356-63. PubMed ID: 10535210
[No Abstract] [Full Text] [Related]
31. Correlation between increased colloid osmotic pressure and the resolution of refractory ascites after transjugular intrahepatic portosystemic shunt.
Schiano TD; Black M; Hills C; Ter H; Bellary S; Miller LS
South Med J; 2000 Mar; 93(3):305-9. PubMed ID: 10728519
[TBL] [Abstract][Full Text] [Related]
32. The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study.
Heiss MM; Ströhlein MA; Bokemeyer C; Arnold D; Parsons SL; Seimetz D; Lindhofer H; Schulze E; Hennig M
Clin Cancer Res; 2014 Jun; 20(12):3348-57. PubMed ID: 24714773
[TBL] [Abstract][Full Text] [Related]
33. Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis.
Seike M; Maetani I; Sakai Y
J Gastroenterol Hepatol; 2007 Dec; 22(12):2161-6. PubMed ID: 18031375
[TBL] [Abstract][Full Text] [Related]
34. Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer.
Harding V; Fenu E; Medani H; Shaboodien R; Ngan S; Li HK; Burt R; Diamantis N; Tuthill M; Blagden S; Gabra H; Urch CE; Moser S; Agarwal R
Br J Cancer; 2012 Sep; 107(6):925-30. PubMed ID: 22878372
[TBL] [Abstract][Full Text] [Related]
35. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
Hamilton CA; Maxwell GL; Chernofsky MR; Bernstein SA; Farley JH; Rose GS
Gynecol Oncol; 2008 Dec; 111(3):530-2. PubMed ID: 18561992
[TBL] [Abstract][Full Text] [Related]
36. Management of non-ovarian cancer malignant ascites through indwelling catheter drainage.
Gu X; Zhang Y; Cheng M; Liu M; Zhang Z; Cheng W
BMC Palliat Care; 2016 Apr; 15():44. PubMed ID: 27103467
[TBL] [Abstract][Full Text] [Related]
37. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Heiss MM; Murawa P; Koralewski P; Kutarska E; Kolesnik OO; Ivanchenko VV; Dudnichenko AS; Aleknaviciene B; Razbadauskas A; Gore M; Ganea-Motan E; Ciuleanu T; Wimberger P; Schmittel A; Schmalfeldt B; Burges A; Bokemeyer C; Lindhofer H; Lahr A; Parsons SL
Int J Cancer; 2010 Nov; 127(9):2209-21. PubMed ID: 20473913
[TBL] [Abstract][Full Text] [Related]
38. Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
Yamaguchi H; Kitayama J; Emoto S; Ishigami H; Ito T; Hanafusa N; Watanabe T
Eur J Surg Oncol; 2015 Jul; 41(7):875-80. PubMed ID: 25986856
[TBL] [Abstract][Full Text] [Related]
39. The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer.
Ayhan A; Günakan E; Alyazıcı İ; Haberal N; Altundağ Ö; Dursun P
Arch Gynecol Obstet; 2017 Nov; 296(5):989-995. PubMed ID: 28875365
[TBL] [Abstract][Full Text] [Related]
40. A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites.
Smart HL; Triger DR
J Hepatol; 1990 Mar; 10(2):191-7. PubMed ID: 2185298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
